Pharmacokinetics of beta-methyldigoxin in subjects with normal and impaired renal function.
Beta-methyldigoxin (beta-MD) was administered orally (0.2 mg) to 24 patients with various degrees of renal function, to investigate its pharmacokinetic characteristics related to renal function. Serum and urine collected until 120 hours after dosing were assayed for beta-MD and digoxin by high-performance liquid chromatography and fluorescence polarization immunoassay method. The steady-state volume of distribution decreased proportionately as creatinine clearance (CLCR) decreased, although steady-state volume of distribution of hemodialysis patients had large interindividual variability, and their mean value was not different from that of patients with normal renal function. Both renal clearance of beta-MD and digoxin were significantly correlated with CLCR (r = .820, P < .001 and r = .822, P < .01, respectively), and the slope of regression line for beta-MD was only 44% that for digoxin. Significantly reduced urinary excretion of total drug (beta-MD plus digoxin) was shown in patients with CLCR below 50 mL/minute/1.48 m2. This study suggests that the dosage modification is not necessary until CLCR decreases to below 50 mL/minute/1.48 m2, but careful attention should be given in the use of beta-MD in patients with CLCR below this value.
Tsutsumi
K
K
Department of Clinical Pharmacology and Therapeutics, Oita Medical University, Japan.
Nakashima
H
H
Tateishi
T
T
Imagawa
M
M
Nakano
S
S
D000328:Adult; D000368:Aged; D002851:Chromatography, High Pressure Liquid; D004077:Digoxin / Q000097:blood / Q000652:urine; D005260:Female; D006785:Hospitals, University; D006801:Humans; D007668:Kidney / Q000378:metabolism* / Q000502:physiology; D007674:Kidney Diseases / Q000378:metabolism* / Q000503:physiopathology; D008297:Male; D008520:Medigoxin / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D008875:Middle Aged
D004077:Digoxin; D008520:Medigoxin